newsdeck
← Back to homepage

AstraZeneca share prices drop amid £300bn mega-merger talks with US rival

Sources
2
Coverage
Limited spectrum
Sentiment
+0.17
◀ Left 100%Centre 0%Right 0% ▶
How we rate bias →
auto_awesome
NEWSDECK ANALYSIS
The Independent Business and Evening Standard report similarly on the potential merger between AstraZeneca and its US rival, noting the significant size of the deal and its potential to create the world's fourth largest pharmaceutical company. Both sources frame the merger as one of the industry's largest ever deals. The Evening Standard describes the talks as being "according to reports", whereas the Independent Business presents the information more directly. The overall tone and emphasis of the two outlets' coverage is broadly in agreement.
This story is currently only covered by 2 sources from a limited part of the political spectrum. NewsDeck will update this page automatically if other outlets pick up the story.
NewsDeck Poll
Do you think this story is being covered fairly across the political spectrum?
Loading…
Left
(2)
Independent Business
Neutral
AstraZeneca share prices drop amid £300bn mega-merger talks with US rival
The merger would mark one of the industry’s largest ever deals and create the world’s fourth largest pharmaceutical company
3 Aug, 09:35
Evening Standard
Neutral
AstraZeneca in talks over £300bn mega-merger with US rival – reports
The move would mark one of the industry’s largest ever deals and create the world’s fourth largest pharmaceutical company.
3 Aug, 07:14
Centre
(0)
No coverage from this perspective yet
Right
(0)
No coverage from this perspective yet